Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics

Cancer

Volumn 118, Issue 23, 2012, Pages 5878-5887

  Italiano, Antoine ^a,b   Chen, Chun Liang ^a   Thomas, Rachael ^c   Breen, Matthew ^c,d   Bonnet, Françoise ^b,e   Sevenet, Nicolas ^b,e   Longy, Michel ^b,e   Maki, Robert G ^f   Coindre, Jean Michel ^b   Antonescu, Cristina R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUT BERGONIÉ   (France)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

angiosarcoma; complex karyotype; p53; phosphatase and tensin homolog; phosphoinositide 3 kinase, catalytic, alpha polypeptide

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; S6 KINASE; UNCLASSIFIED DRUG;

4EBP1 GENE; AKT GENE; ANGIOSARCOMA; ARTICLE; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; GENE; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE INSERTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOMICS; HDM2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MTOR GENE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; P14 GENE; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PS6K GENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, P53; GENOMICS; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84869505772     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27614     Document Type: Article

References (55)

1. Fletcher CD, Unni K, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
2. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007; 18: 2030-2036. (Pubitemid 350286245)
3. Mandahl N, Jin YS, Heim S, et al. Trisomy 5 and loss of the Y chromosome as the sole cytogenetic anomalies in a cavernous hemangioma/angiosarcoma. Genes Chromosomes Cancer. 1990; 1: 315-316. (Pubitemid 20218518)
4. Kindblom LG, Stenman G, Angervall L,. Morphological and cytogenetic studies of angiosarcoma in Stewart-Treves syndrome. Virchows Arch A Pathol Anat Histopathol. 1991; 419: 439-445.
5. Gil-Benso R, Lopez-Gines C, Soriano P, Almenar S, Vazquez C, Llombart-Bosch A,. Cytogenetic study of angiosarcoma of the breast. Genes Chromosomes Cancer. 1994; 10: 210-212. (Pubitemid 24198761)
6. Van den Berg E, Van Oven MW, de Jong B, et al. Comparison of cytogenetic abnormalities and deoxyribonucleic acid ploidy of benign, borderline malignant, and different grades of malignant soft tissue tumors. Lab Invest. 1994; 70: 307-313. (Pubitemid 24116524)
7. Cerilli LA, Huffman HT, Anand A,. Primary renal angiosarcoma: a case report with immunohistochemical, ultrastructural, and cytogenetic features and review of the literature. Arch Pathol Lab Med. 1998; 122: 929-935. (Pubitemid 28485278)
8. Wong KF, So CC, Wong N, Siu LL, Kwong YL, Chan JK,. Sinonasal angiosarcoma with marrow involvement at presentation mimicking malignant lymphoma: cytogenetic analysis using multiple techniques. Cancer Genet Cytogenet. 2001; 129: 64-68. (Pubitemid 32743382)
9. Zu Y, Perle MA, Yan Z, Liu J, Kumar A, Waisman J,. Chromosomal abnormalities and p53 gene mutation in a cardiac angiosarcoma. Appl Immunohistochem Mol Morphol. 2001; 9: 24-28. (Pubitemid 32179106)
10. Baumhoer D, Gunawan B, Becker H, Fuzesi L,. Comparative genomic hybridization in 4 angiosarcomas of the female breast. Gynecol Oncol. 2005; 97: 348-352. (Pubitemid 40614874)
11. Cao Y, Zou SM, Zhang KT, et al. Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. Histol Histopathol. 2011; 26: 491-496.
12. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol. 2010; 176: 34-39.
13. Guo T, Chang NE, Singer S, Maki RG, Antonescu CR,. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011; 50: 25-33.
14. Mao JH, Wu D, Perez-Losada J, Nagase H, DelRosario R, Balmain A,. Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene. 2003; 22: 8379-8385. (Pubitemid 37523889)
15. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436: 725-730. (Pubitemid 41117277)
16. Cully M, You H, Levine AJ, Mak TW,. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6: 184-192. (Pubitemid 43292562)
17. Hambardzumyan D, Becher OJ, Rosenblum MK, et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008; 22: 436-448. (Pubitemid 351272752)
18. Kwon CH, Zhao D, Chen J, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 2008; 68: 3286-3294.
19. Zheng H, Ying H, Yan H, Kimmelman AC, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008; 455: 1129-1133.
20. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009; 23: 675-680.
21. Perot G, Chibon F, Montero A, et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol. 2010; 177: 2080-2090.
22. Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011; 117: 5359-5369.
23. Ito M, Barys L, O'Reilly T, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res. 2011; 17: 416-426.
24. Yang J, Du X, Chen K, et al. Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett. 2009; 275: 1-8.
25. Gibault L,. Recurrent Genomic Alterations in Sarcomas With Complex Genomics: PTEN and DKK1 Loss of Expression, Mechanisms and Biological Consequences [PhD thesis]. Paris, France: University Paris Descartes; 2010.
26. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007; 13: 748-753. (Pubitemid 46889749)
27. Hollstein M, Marion MJ, Lehman T, et al. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis. 1994; 15: 1-3. (Pubitemid 24121615)
28. Soini Y, Welsh JA, Ishak KG, Bennett WP,. p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis. 1995; 16: 2879-2881.
29. Naka N, Tomita Y, Nakanishi H, et al. Mutations of p53 tumor-suppressor gene in angiosarcoma. Int J Cancer. 1997; 71: 952-955. (Pubitemid 27252874)
30. Zietz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998; 153: 1425-1433. (Pubitemid 28509898)
31. Amo Y, Masuzawa M, Hamada Y, Katsuoka K,. Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation. Acta Derm Venereol. 2002; 82: 373-374. (Pubitemid 35221791)
32. Weihrauch M, Bader M, Lehnert G, et al. Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen. 2002; 40: 36-40. (Pubitemid 34848036)
33. Domfeh AB, Fichera M, Hunt JL,. Allelic loss of 3 different tumor suppressor gene loci in benign and malignant endothelial tumors of the head and neck. Arch Pathol Lab Med. 2006; 130: 1184-1187. (Pubitemid 44168788)
34. Tate G, Suzuki T, Mitsuya T,. Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007; 178: 160-162. (Pubitemid 47588422)
35. Santi R, Cetica V, Franchi A, et al. Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy. Histopathology. 2011; 58: 455-466.
36. Thomas R, et al. Leukemia and Lymphoma. 2011; 52: 1321-1335.
37. Weber J, Miserere S, Champ J, et al. High-throughput simultaneous detection of point mutations and large-scale rearrangements by CE. Electrophoresis. 2007; 28: 4282-4288. (Pubitemid 350259029)
38. Caux-Moncoutier V, Castera L, Tirapo C, et al. EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat. 2011; 32: 325-334.
39. Cordon-Cardo C, Reuter VE,. Alterations of tumor suppressor genes in bladder cancer. Semin Diagn Pathol. 1997; 14: 123-132. (Pubitemid 27233150)
40. Mallofre C, Castillo M, Morente V, Sole M,. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003; 16: 187-191. (Pubitemid 36337422)
41. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009; 69: 7175-7179.
42. Whibley C, Pharoah PD, Hollstein M,. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009; 9: 95-107.
43. Das P, Kotilingam D, Korchin B, et al. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer. 2007; 109: 2323-2333. (Pubitemid 46801564)
44. Robles AI, Harris CC,. Clinical outcomes and correlates of TP53 mutations and cancer [abstract]. Cold Spring Harb Perspect Biol. 2010; 2: a001016.
45. Caux F, Plauchu H, Chibon F, et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet. 2007; 15: 767-773. (Pubitemid 46965410)
46. Dimmeler S, Zeiher AM,. Akt takes center stage in angiogenesis signaling. Circ Res. 2000; 86: 4-5. (Pubitemid 30044160)
47. Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 1997; 276: 1848-1850. (Pubitemid 27443659)
48. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK,. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A. 1998; 95: 14950-14955. (Pubitemid 29003737)
49. Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S,. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol. 2008; 17: 159-165.
50. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010; 42: 715-721.
51. Carracedo A, Pandolfi PP,. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008; 27: 5527-5541.
52. Schuetze SM, Baker LH, Maki RG,. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. J Clin Oncol. 2006; 24: 9503.
53. Bundscherer A, Vogt T, Kohl G, Landthaler M, Hafner C,. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. Anticancer Res. 2010; 30: 4017-4023.
54. LaMontagne KR Jr, Moses MA, Wiederschain D, et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000; 157: 1937-1945.
55. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27: 3133-3140.